Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Fat interferes with body's sugar sensors to trigger type 2 diabetes

Fat interferes with body's sugar sensors to trigger type 2 diabetes

Metabolic profile reveals need for gender-specific therapies

Metabolic profile reveals need for gender-specific therapies

Pre-emptive insulin therapy reduces risk of diabetes mellitus after kidney transplantation

Pre-emptive insulin therapy reduces risk of diabetes mellitus after kidney transplantation

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Metabolic syndrome linked to increased risk of primary liver cancers

Metabolic syndrome linked to increased risk of primary liver cancers

Series of articles explore recent evidence-based vascular medicine

Series of articles explore recent evidence-based vascular medicine

Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee

Investigational compound dapagliflozin receives negative recommendation from FDA Advisory Committee

Regular physical activity may reduce rates of cognitive impairment in older adults

Regular physical activity may reduce rates of cognitive impairment in older adults

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

Peak of Australian flu season is imminent so take the necessary precautions now: Experts

IQWiG finds no differences between two treatment strategies for type 2 diabetes

IQWiG finds no differences between two treatment strategies for type 2 diabetes

Poisonous shrub extract may act as natural painkiller

Poisonous shrub extract may act as natural painkiller

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Preliminary results from Generex Oral-lyn clinical trial on type 1 diabetes

Exenatide tQT clinical trial meets pre-specified primary endpoint

Exenatide tQT clinical trial meets pre-specified primary endpoint

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

Tibotec, Gilead Sciences enter license agreement for new combination product of PREZISTA and cobicistat

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

Very low calorie diet can reverse type 2 diabetes: Study

Very low calorie diet can reverse type 2 diabetes: Study

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.